Clinical Trials Browser

Phase 2 × INDUSTRY × reparixin × Clear all

NCT05212701 2024-04-30

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Fatigue

NCT01861054 2021-05-14

Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

Phase 2 Terminated

20 enrolled 16 charts

Breast Neoplasms